Bausch + Lomb and Novaliq Announce Submission of New Drug Application for Investigational Treatment NOV03 (perfluorohexyloctane)


VAUGHAN, ON and HEIDELBERG, Germany, July 7, 2022 /PRNewswire/ — Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better , and Novaliq GmbH, a biopharmaceutical company focused on first-in-class and best-in-class ocular therapeutics, today announced the submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA) in late June. from the United States to seek approval of NOV03 (perfluorohexyloctane), an investigational treatment with a proposed indication for the treatment of signs and symptoms of dry eye disease (DED) associated with meibomian gland dysfunction (MGD) .

“We are excited to have the potential to advance the care of people with dry eye disease associated with meibomian gland dysfunction. If approved by the FDA, NOV03 will be the first available treatment indicated to treat the signs and symptoms in this patient population,” said Joseph C. Papa, Chairman and CEO of Bausch + Lomb. “The NOV03 case is an example of Bausch + Lomb’s commitment to bringing new treatment options to the industry so that we can better serve patients.”

DED is one of the most common ocular surface disorders, with approximately 18 million Americans diagnosed with DED.1.2 MGD is a major cause of the development and progression of evaporative DED, which is caused by a deficient lipid layer in the tear film that leads to increased tear evaporation.3 In one study, it was found that approximately 86% of DED patients had MGD involvement.4

“We are working hand-in-hand with Bausch + Lomb to bring this new treatment option, if approved, to the optometric and ophthalmic community so they can help meet the needs of patients with dry eye disease associated with dysfunction. of the meibomian gland,” said Christian Rosky, Ph.D., CEO, Novaliq. “This New Drug Application Submission is a critical milestone and the first drug submission for a waterless therapy. We are excited to unleash the full potential of NOV03 by providing this new drug option for this condition at United States.”

About NOV03 (Perfluorohexyloctane) Ophthalmic Solution
NOV03 is an experimental, exclusive, water-free and preservative-free eye drop.5 In 2019, Bausch + Lomb acquired an exclusive license for the commercialization and development of NOV03 in the United States and Canada. Data from the first pivotal Phase 3 (GOBI) trial evaluating NOV03 (perfluorohexyloctane) was presented at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in washington d.c. on April 24, 2022. Data from the second pivotal Phase 3 trial (MOJAVE) was presented at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in denver on May 2, 2022. The results of the pivotal phase 2 trial (SEECASE) have been published in Cornea in September 2021.6 The clinical program for NOV03 has concluded with the completion of a 12-month, single-arm, open-label, multicenter safety extension trial (KALAHARI).

About Novaliq
Novaliq is a biopharmaceutical company focused on the development and commercialization of premium ocular therapeutic products based on EyeSol®, the world’s first waterless technology. Novaliq offers an industry-leading portfolio that addresses the current unmet medical needs of millions of eye disease patients. Novaliq GmbH is headquartered in Heidelberg, Germany, and Novaliq Inc. has an office in Cambridge, MA, USA. The long-term shareholder is dievini Hopp BioTech holding GmbH & Co. KG, an active investor in life sciences and healthcare companies. More information at

About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every stage of life. Its comprehensive portfolio of over 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products, and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and sales footprint with more than 12,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, ON with headquarters in Bridgewater, New Jersey. For more information, visit and contact us at TwitterLinkedIn, Facebook and Instagram.

Forward-looking statements
This press release may contain forward-looking statements, which can generally be identified by the use of the words “anticipates”, “hopes”, “expects”, “intends”, “expects”, “should ‘, ‘could’, ‘would’, ‘may’, ‘believes’, ‘estimates’, ‘potential’, ‘target’ or ‘continues’ and similar variations or expressions. These statements are based on management’s current expectations and beliefs and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the United States Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated into present by reference. They also include, but are not limited to, the risks and uncertainties caused by or related to the evolution of the COVID-19 pandemic, as well as the fear of this pandemic and its potential effects, including the severity, duration and future impact are highly uncertain and cannot be predicted, and which could have a material adverse impact on Bausch + Lomb, including, but not limited to, delays in its project development, launches and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual results, except as required by law.


  1. Leonardi, A., Modugno, RL and Salami, E. (2021). Allergy and dry eye. Ocular immunology and inflammation, 29(6), 1168-1176.

  2. Dry Eye Products Market Report 2020: A Global Analysis from 2019 to 2025. Market Scope. Retrieved from

  3. Geerling, Gerd et al. “Emerging Strategies for the Diagnosis and Treatment of Meibomian Gland Dysfunction: Proceedings of the OCEAN Group Meeting.” The ocular surface flight. 15.2 (2017): 179-192. doi:10.1016/j.jtos.2017.01.006.

  4. Lemp, MA, Crews, LA, Bron, AJ, Foulks, GN and Sullivan, BD (2012). Distribution of water-deficient and evaporative dry eye disease in a cohort of clinical patients: a retrospective study. Cornea, 31(5), 472–478. doi: 10.1097/ICO.0b013e318225415a.

  5. In December 2019Bausch Health has acquired the rights from Novaliq GmbH to continue the development and commercialization of NOV03 for DED and combination products based on NOV03 in additional ophthalmic indications in United States and Canada.

  6. Tauber J, Wirta DL, Sall K, Majmudar PA, Willen D, Krösser S; SEECASE study group. A randomized clinical study (SEECASE) to evaluate the efficacy, safety and tolerability of NOV03 for the treatment of dry eye disease. Cornea. 2021; 40(9):1132-1140.

All product/brand names and/or logos are trademarks of their respective owners.
© 2022 Bausch & Lomb Incorporated or its affiliates.

Bausch + Lomb (PRNewsfoto/Bausch + Lomb)



See original content to download multimedia:–lomb-and-novaliq-announce-submission-of-new-drug-application-for-investigational-treatment- nov03-perfluorohexyloctane-301581930.html

SOURCEBausch + Lomb Corporation


Comments are closed.